New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
Government Shutdown Stymies U.S. Research Efforts
New Rochelle, NY, October 16, 2013—Over 73% of U.S. scientists responding to a Genetic Engineering & Biotechnology News (GEN) poll say that the current government shutdown is impacting their ability to carry out their research projects.
According to the GEN survey question, “Has the government shutdown affected your research projects?,” 39.7% replied significantly; 21.8% said moderately; 12% responded slightly; and 26.5% were not affected at all.
The results of the GEN survey echo the thoughts of officials at the American Society for Cell Biology, the Ludwig Institute for Cancer Research, and the University of California, San Diego. Their consensus was that American political shortsightedness has huge ramifications for the life science community right now and will continue to do so for the future. (You can read the story here.)
“Not only do these kinds of government actions hurt U.S. competitiveness on the global biotechnology stage but, more importantly, it hinders scientists’ abilities to come up with life-saving drugs and effective therapies for a host of serious diseases,” says John Sterling, editor in chief of GEN.